## Supplementary figures



Figure S1. Comparison of the mean number of complement receptor 1 per erythrocyte (CR1/E) and soluble CR1 (sCR1) in AD patients according to stage of AD. Box plots of CR1/E are shown. The upper and lower limits of the boxes, and the middle line across the boxes indicate the 75th and 25th percentiles, and the median, respectively. The upper and lower horizontal bars indicate the maximum and minimum values, respectively. A Student's $t$-test was used for normally distributed variables; ${ }^{*} p=0.034$. (a) Comparison of the mean number of CR1/E in AD patients according to the stage of AD . (b) Comparison of the level of sCR1 in AD patients according to the stage of AD.


Figure S2. DNA sequence alignment of the high-resolution melting PCR (HRM-PCR) amplicons, and positions of the methylated sites according to the genomic reference sequence (NG 007481.1) corresponding to the long allele of CR1 (CR1*2). Two areas of the long homologous region B (LHR-B) of CR1 are amplified at positions 48743 to 48960 and 67300 to 67517 , corresponding to the LHR-B segments, and one area is amplified at position 84358 to 84574 , corresponding to the LHR-C segment. The positions of the five methylated sites (SM1, SM2, SM3, SM4, and SM5) are framed in color. In blue, SM1 is located at positions 48858, 67415, and 84472, SM3 is located at positions 48919,67476 , and 84533 , SM4 is located at positions 48925,67482 , and 84539 , and SM5 is located at positions 48939,67496 , and 84553 . In orange, SM2 is located at positions 48895 and 67452 , but is missing at position 84509 .

## Supplementary tables

Table S1 Univariate linear regression between CR1/E density and MMSE score as a quantitative variable (values $0-30$ ) and as a qualitative variable in two classes (Mild: 21 to 30 vs. moderate/severe: 0 to 20).

| Variable | Unit | Estimate | $95 \%$ CIs | $p$ |
| :---: | :---: | :---: | :---: | :---: |
| MMSE score | 1 | 10.09 | $-0.01,20.19$ | 0.0503 |
| MMSE score (reference: mild) | - | -115.08 | $-221.78,-8.39$ | 0.035 |

Table S2 Univariate linear regression between SCR1 rate and MMSE score, as a quantitative variable (values 030) and as a qualitative variable in two classes (Mild: 21 to 30 vs. moderate/severe: 0 to 20).

| Variable | Unit | Estimate | $95 \%$ CIs | $p$ |
| :---: | :---: | :---: | :---: | :---: |
| MMSE score | 1 | 0.00 | $-0.88,0.88$ | 0.995 |
| MMSE score (reference: mild) | - | -1.12 | $-10.45,8.21$ | 0.812 |

Table S3 Univariate analysis of density and covariates, ordered by $p$-value.

| Variable | Unit | Estimate | 95\% CIs | $p$ |
| :---: | :---: | :---: | :---: | :---: |
| Density polymorphism Q981H (reference: HH) | - |  |  | $<0.001$ |
| HQ | - | 146.844 | -25.121, 318.81 |  |
| QQ | - | 444.839 | 278.477, 611.2 |  |
| Density polymorphism HindIII (reference: HH) | - |  |  | <0.001 |
| HL | - | -289.341 | -363.063, -215.62 |  |
| LL | - | -530.712 | -704.195, -357.229 |  |
| Alzheimer's disease | - | -110.591 | -192.73, -28.453 | 0.009 |
| Age | 1 | -3.809 | -9.201, 1.584 | 0.165 |
| APOE-84+ | - | 56.432 | -28.745, 141.609 | 0.193 |
| Length polymorphism (reference: CR1* ${ }^{*}$ ) | - |  |  | 0.201 |
| CR1* 1 CR1*2 | - | -105.815 | -203.176, -8.455 |  |
| CR1*2 | - | -92.002 | -277.965, 93.961 |  |
| CR1*2 CR1*4 | - | -290.902 | -859.469, 277.665 |  |
| CR1*3 CR1*1 | - | -95.902 | -499.495, 307.691 |  |
| HRM (reference: EF) | - |  |  | 0.281 |
| F | - | 93.79 | -310.839, 498.419 |  |
| FS | - | 0.042 | -409.692, 409.775 |  |
| S | - | 3.9 | -435.872, 443.672 |  |
| T | - | -195 | -890.341, 500.341 |  |
| $4^{\text {th }}$ methylation site | 1\% | 3.742 | -3.308, 10.791 | 0.296 |
| $1{ }^{\text {st }}$ methylation site | 1\% | -2.276 | -6.868, 2.317 | 0.329 |
| Sex (reference: male) | - | -29.151 | -115.062, 56.76 | 0.504 |
| $3{ }^{\text {st }}$ methylation site | 1\% | -1.356 | -6.203, 3.49 | 0.581 |
| Mean methylation | 1\% | -1.678 | -9.066, 5.71 | 0.655 |
| $2^{\text {nd }}$ methylation site | 1\% | 0.886 | -5.948, 7.721 | 0.798 |
| $5{ }^{\text {st }}$ methylation site | 1\% | 0.483 | -5.587, 6.553 | 0.875 |

CR1 = complement receptor $1 ; 95 \%$ CIs $=95 \%$ confidence intervals.

Table S4 Tests of interaction.

| Interactions | $p$ |
| :---: | :---: |
| Length polymorphism $\times$ APOE4 | 0.406 |
| Length polymorphism $\times$ Alzheimer's disease | 0.263 |
| APOE4 $\times$ Alzheimer's disease | 0.344 |
| Age $\times$ Alzheimer's disease | 0.477 |

